Publications by authors named "Frank Lieberman"

Claim this Profile
A
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.
Patrick Y Wen, Andrea Manzanera, Caroline Duault, Edgar Gonzalez-Kozlova, Lenika Lopez, Frank Lieberman

Neuro Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek, Frank Lieberman

Sci Transl Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast Hadamard-Encoded 7T Spectroscopic Imaging of Human Brain.
Chan Hong Moon, Frank S Lieberman, Hoby P Hetherington, Jullie W Pan

Tomography· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek, Frank Lieberman

medRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert, Frank S Lieberman

Neurooncol Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR).
Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, Xiaobu Ye, Matthias Holdhoff, Frank S Lieberman

Cell Rep Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma.
Stephanie M Casillo, Taylor A Gatesman, Akanksha Chilukuri, Srinidhi Varadharajan, Brenden J Johnson, Frank S Lieberman

Cell Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, Glen H J Stevens, Hui-Kuo Shu, Frank Lieberman

J Neurooncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Roy Strowd, Benjamin Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y Wen, Frank S Lieberman

J Neurooncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM).
Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, Glenn H J Stevens, Hui-Kuo Shu, Frank Lieberman

Res Sq· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
Megan Mantica, Jan Drappatz, Frank Lieberman, Constantinos G Hadjipanayis, L Dade Lunsford

J Neurooncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Michal Nisnboym, Sarah R Vincze, Zujian Xiong, Chaim T Sneiderman, Rebecca A Raphael, Frank S Lieberman

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent and -mutant Glioma.
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Frank Scott Lieberman

Cancer Res Commun· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Added Value of Family Caregivers' Level of Mastery in Predicting Survival of Glioblastoma Patients: A Validation Study.
Florien W Boele, Jason Weimer, Amir H Zamanipoor Najafabadi, Louise Murray, Charles W Given, Frank S Lieberman

Cancer Nurs· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.
Brian J Golbourn, Matthew E Halbert, Katharine Halligan, Srinidhi Varadharajan, Brian Krug, Frank Lieberman

Nat Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.
Brian J Golbourn, Matthew E Halbert, Katharine Halligan, Srinidhi Varadharajan, Brian Krug, Frank Lieberman

Nat Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Itay Raphael, Rajeev Kumar, Lauren H McCarl, Karsen Shoger, Lin Wang, Frank S Lieberman

Front Immunol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Mark R Gilbert, Ying Yuan, Jimin Wu, Tito Mendoza, Elizabeth Vera, Frank Lieberman

Neuro Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
David M Peereboom, Xiaobu Ye, Tom Mikkelsen, Glenn J Lesser, Frank S Lieberman

Neurosurgery· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Huanwen Chen, John Kuhn, Kathleen R Lamborn, Lauren E Abrey, Lisa M DeAngelis, Frank Lieberman

Neurooncol Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Eudocia Q Lee, Michael Weller, Joohee Sul, Stephen J Bagley, Solmaz Sahebjam, Frank S Lieberman

Neuro Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.
H Ian Robins, Jens Eickhoff, Mark R Gilbert, Terri S Armstrong, Wenyin Shi, Frank S Lieberman

Neurooncol Pract· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric Evaluation of the Caregiver Needs Screen in Neuro-Oncology Family Caregivers.
Florien W Boele, Lauren Terhorst, Jennifer Prince, Heidi S Donovan, Jason Weimer, Frank S Lieberman

J Nurs Meas· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Frank S Lieberman, Meihua Wang, H Ian Robins, Christina I Tsien, Walter J Curran

Int J Radiat Oncol Biol Phys· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
Michael S Dressen, Ashok Muthukrishnan, Tyson R Tragon, Frank S Lieberman, James M Mountz

Clin Nucl Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis